Tarek Persaud, MD
Retina Specialist · Huntsville, ALNPI 1073578589
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $750 of the $1,030 with a category attached, or 72.8%. 8 manufacturers reported payments, led by Ocular Therapeutix, Inc. at 27.2% of the total.
Across 21 payments — averaging $49.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$280
- AbbVie$268
- Regeneron Healthcare Solutions, Inc.$203
- Alcon$149
- Genentech USA, Inc.$53
- Alimera Sciences, Inc.$33
- plus $43 from 2 others
What the payments were for
- Food & beverage$75073%
- Other$28027%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 2 | $280 |
| AbbVie(2 entities) | 7 | $268 |
| Regeneron Healthcare Solutions, Inc. | 4 | $203 |
| Alcon | 1 | $149 |
| Genentech USA, Inc. | 3 | $53 |
| Alimera Sciences, Inc. | 2 | $33 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Biogen | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXTENZA$280
- Constellation$149
- XEN$146
- EYLEA$143
How this compares
$1,030 in reported general payments places this provider in the 55th percentile of 21 retina specialist providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 68 | $6,943 |
| Prednisolone Acetate | 123 | $6,139 |
| TobradexTobramycin/Dexamethasone | 12 | $2,878 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 53 | $2,442 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $1,646 |
| Atropine Sulfate | 47 | $1,595 |
| Loteprednol Etabonate | 11 | $1,445 |
| Gentamicin Sulfate | 94 | $870 |
| Latanoprost | 21 | $310 |
| Cyclopentolate Hcl | 17 | $185 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Huntsville
- Alexander TalalightHuntsville$4K
- Vikram SainiHuntsville$1K
- Edgar ReadyHuntsville$1K
- James ByrneHuntsville$352
- Nancy MedeirosHuntsville$241
- Alan FranklinMobile$97K
- Jeffrey FullerBirmingham$15K
- Larry BrownBirmingham$4K
- Andrew HsiaMontgomery$2K
- Tyler RowseyBirmingham$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.